Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) (DBCOND0092771)

Identifiers

Synonyms

Myelodysplastic Syndrome With Excess Blasts-2 / Myelodysplastic neoplasm with increased blasts-2 (morphologic abnormality) / Myelodysplastic syndrome with excess blasts 2 / Refractory anemia with excess of blasts 2 / Myelodysplastic syndrome with excess blasts-2 (disorder)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03338348	Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2	Azacitidine Vosaroxin	treatment	2	completed
NCT03839771	A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy	Enasidenib Ivosidenib	treatment	3	active_not_recruiting
NCT04027309	A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy	Gilteritinib Midostaurin	treatment	3	active_not_recruiting
NCT05703542	BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome	Talabostat	treatment	1	recruiting
NCT02530034	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies	No drug interventions	treatment	1	active_not_recruiting
NCT03850574	Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Tuspetinib Venetoclax	treatment	1 / 2	recruiting
NCT01858740	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	Fludarabine Methopterin Methotrexate Tacrolimus Thiotepa Tromethamine	treatment	2	completed
NCT04526288	CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease	Cytarabine Daunorubicin	treatment	2	terminated
NCT02220985	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	Cyclophosphamide Fludarabine Methopterin Methotrexate Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	active_not_recruiting
NCT06247917	Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS	Busulfan Fludarabine Melphalan	treatment	2	recruiting
NCT02756572	Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms	Cladribine Cyclosporine Cytarabine Filgrastim Fludarabine Mechlorethamine Melphalan Mitoxantrone Mycophenolate mofetil Sirolimus	treatment	2	completed